Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.70 |
| ▸ | MAOA | P21397 | 6/20 | 0.70 |
| ▸ | ACHE | P22303 | 13/20 | 0.64 |
| ▸ | BCHE | P06276 | 2/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6263327 | 0.99 | MAOB (0.68) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL15790525 | 0.84 | MAOB (0.72) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL4188273 | 0.82 | MAOA (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL332172 | 0.82 | MAOB (0.70) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL4186594 | 0.82 | MAOA (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL4186601 | 0.82 | MAOA (1.00) | MAOBMAOAACHEBCHEADRA2B | |
| Hydrochloric Acid SCHEMBL7336795 | 0.81 | MAOB (0.68) | MAOBMAOAACHEBCHEADRA2B | |
| Hydrochloric Acid SCHEMBL7342056 | 0.81 | MAOA (0.68) | MAOBMAOAACHEBCHEADRA2B | |
| SCHEMBL15790524 | 0.80 | MAOB (0.67) | MAOBMAOAACHEBCHEADRA2B | |
| Rasagiline SCHEMBL2827373 | 0.78 | MAOB (1.00) | MAOBMAOAACHEBCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006014968-A2 | PROPARGYL NITROXYDES AND INDANYL NITROXIDES AND THEIR USE FOR THE TREATMENT OF NEUROLOGIC DISEASES AND DISORDERS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-02-09 | — | — | WO | disclosed |
| WO-2005084205-A2 | DIAMINO THIAZOLOINDAN DERIVATIVES AND THEIR USE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | RTN3, RTN4, DRD4 | MAOB 174/4885MAOA 207/4885ACHE 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.